Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Triple-negative breast cancer.

Rupert Bartsch1, Reinhard Ziebermayr, Christoph C Zielinski

  • 1Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, Vienna, Austria. rupert.bartsch@meduniwien.ac.at

Wiener Medizinische Wochenschrift (1946)
|May 18, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Breast (Edinburgh, Scotland)·2026
Same author

Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort.

Life (Basel, Switzerland)·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department.

BMC infectious diseases·2026
Same author

AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Triple-negative breast cancer lacks targeted therapies. Combining PARP-1 inhibitors with platinum drugs shows promise, offering a potentially highly active and specific treatment option for patients at high risk of recurrence.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies, unlike endocrine-responsive and HER2-positive subtypes.
  • Patients with TNBC face a high risk of tumor recurrence.
  • Current treatment options for TNBC are limited, with platinum-based chemotherapy showing some activity but lacking prospective validation.

Purpose of the Study:

  • To explore targeted therapeutic strategies for triple-negative breast cancer.
  • To investigate the potential of novel drug combinations for TNBC treatment.
  • To address the unmet need for specific therapies in high-risk TNBC patients.

Main Methods:

  • Review of preclinical and limited clinical data on platinum-based regimens for TNBC.
  • Evaluation of agents targeting tumor angiogenesis, such as bevacizumab.

Related Experiment Videos

Last Updated: Jun 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

  • Analysis of emerging research on drugs targeting DNA-damage repair pathways, specifically PARP-1 inhibitors.

    • Main Results:

    • Platinum-based regimens are suggested as the most active conventional chemotherapy for TNBC, though prospective trials are needed.
    • Anti-angiogenic agents show activity across breast cancer subtypes but are not specific to TNBC.
    • PARP-1 inhibitors combined with platinum derivatives demonstrated a significant survival benefit over chemotherapy alone in a Phase II study.

    Conclusions:

    • The combination of PARP-1 inhibitors and platinum derivatives represents a promising targeted approach for triple-negative breast cancer.
    • This therapeutic strategy offers the potential for highly active and specific treatment for TNBC.
    • Further research and prospective trials are warranted to validate these findings and optimize treatment for TNBC.